ReviewMolecular and cellular endocrinology2011
Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?
Review in Molecular and cellular endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Differential response to targeted acupuncture by gender in patients with gastrointestinal cancer cachexia: secondary analysis of a randomized controlled trial.Acupuncture in medicine : journal of the British Medical Acupuncture Society · 2020Trial
- Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study.Integrative cancer therapiesTrial
- The LEAP2 Response to Cancer-Related Anorexia-Cachexia Syndrome in Male Mice and Patients.Endocrinology · 2024Article
- The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective study based on a large population.Cancer medicine · 2023Article
- Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies.Frontiers in physiology · 2022Review
- In silico strategy for detailing the binding modes of a novel family of peptides proven as ghrelin receptor agonists.Journal of molecular modeling · 2020Article
- Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery.International journal of molecular sciences · 2020Review
- Article
- Ghrelin Receptor Agonist Rescues Excess Neonatal Mortality in a Prader-Willi Syndrome Mouse Model.Endocrinology · 2018Article
- Ghrelin therapy improves lung and cardiovascular function in experimental emphysema.Respiratory research · 2017Article
- Cancer anorexia: hypothalamic activity and its association with inflammation and appetite-regulating peptides in lung cancer.Journal of cachexia, sarcopenia and muscle · 2017Observational
- From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.International journal of molecular sciences · 2017Review
- An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin.Clinical pharmacology in drug development · 2015Article
- Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor.British journal of pharmacology · 2014Article
- Research on cachexia, sarcopenia and skeletal muscle in cardiology.Journal of cachexia, sarcopenia and muscle · 2012Article
- Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy.CNS drugs · 2012Review
- The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism.Current pharmaceutical design · 2012Review
- Use of ghrelin as a treatment for inflammatory bowel disease: mechanistic considerations.International journal of peptides · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cachexia is a syndrome of wasting and anorexia that worsens the prognosis of many chronic diseases including cancer, chronic kidney disease, chronic heart disease and chronic obstructive pulmonary disease. Properties of the orexigenic hormone ghrelin-including appetite-stimulation, weight-gain production and increased cardiac output make it a logical treatment for cachexia. While endogenous ghrelin levels are increased in the setting of cachexia, treatment with ghrelin and other GHSR-1a agonists in animal models of cachexia and in humans with cachexia has demonstrated consistent effects of increased appetite and improved weight gain. These positive effects occur in multiple underlying diseases associated with cachexia and appear to be sustained over treatment duration of up to 12 weeks. The mechanism of action in producing these effects is likely related to stimulation of central appetite centers such as the central melanocortin system and to increased growth hormone release, though ghrelin's effects may also relate to decreased systemic inflammation and other direct and indirect actions. Questions regarding the long-term safety of ghrelin treatment are still unanswered, as is the important question of whether successful treatment of cachexia will improve the prognosis of the underlying disease itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.